Fujifilm Biotechnologies moved to scale manufacturing readiness after its Holly Springs, North Carolina commercial-scale cell culture site was selected for the FDA’s PreCheck Pilot Program. The initiative aims to strengthen U.S. pharmaceutical manufacturing capabilities by integrating earlier, pre-approval quality readiness review. The company also detailed ongoing expansion plans at the Holly Springs biomanufacturing complex, including additional 20,000 L mammalian bioreactors, and described an announced manufacturing customer for the second phase tied to argeX. Fujifilm highlighted investments in quality control capacity, including a dedicated QC laboratory in Denmark with robotics and viral safety testing. The operational buildout includes digital systems such as LIMS to support data integrity and harmonization across sites. For biotech leaders, the FDA pilot selection signals continued momentum for faster, more predictable quality systems as sponsors pursue complex biologics scale-up and launch planning.